Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
542 questions in 42 reviews · Skin
current versionsNo studies 542 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acyclovir + calamine + cetirizine vs calamine + cetirizine The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir + calamine + cetirizine vs calamine + cetirizine The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir vs erythromycin The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Acyclovir vs erythromycin Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Clarithromycin vs placebo Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Clarithromycin vs placebo Minor participant‐reported adverse events not requiring withdrawal of the treatment · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs placebo The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs placebo The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea Interventions for pityriasis rosea (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Severe skin drug‐induced rash · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen… Genetic testing for prevention of severe drug‐induced skin rash (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Long‐term sequelae · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen… Genetic testing for prevention of severe drug‐induced skin rash (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospitalisation for drug‐induced skin reaction · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen… Genetic testing for prevention of severe drug‐induced skin rash (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR SJS/TEN (Stevens‐Johnson syndrome/toxic epidermal necrolysis) · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen… Genetic testing for prevention of severe drug‐induced skin rash (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR AGEP (acute generalised exanthematous pustulosis) · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen… Genetic testing for prevention of severe drug‐induced skin rash (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Death · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen… Genetic testing for prevention of severe drug‐induced skin rash (2019) · Cochrane | no estimate extracted | NR | No studies |
Biotin vs placebo Quality of life · infantile seborrhoeic dermatitis (including cradle cap) Interventions for infantile seborrhoeic dermatitis (including cradle cap) (2019) · Cochrane | no estimate extracted | NR | No studies |
Proprietary products vs placebo Quality of life · infantile seborrhoeic dermatitis (including cradle cap) Interventions for infantile seborrhoeic dermatitis (including cradle cap) (2019) · Cochrane | no estimate extracted | NR | No studies |
Topical steroids vs comparator Quality of life · infantile seborrhoeic dermatitis (including cradle cap) Interventions for infantile seborrhoeic dermatitis (including cradle cap) (2019) · Cochrane | no estimate extracted | NR | No studies |
Intravenous soya oil‐derived (n‐6) fatty acid‐based lipid emulsion vs intravenous fish oil‐derived (n‐3) fatty acid‐based lipid emulsion Percentage of participants clear or almost clear, i.e. obtaining PASI 100/90 and/or PGA of 0 or 1 in the short term · guttate psoriasis Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Intravenous soya oil‐derived (n‐6) fatty acid‐based lipid emulsion vs intravenous fish oil‐derived (n‐3) fatty acid‐based lipid emulsion Percentage of participants with adverse effects and severe adverse effects · guttate psoriasis Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Intravenous soya oil‐derived (n‐6) fatty acid‐based lipid emulsion vs intravenous fish oil‐derived (n‐3) fatty acid‐based lipid emulsion Number of relapses of guttate psoriasis or flares within a period of 6 months after the treatment has finished · guttate psoriasis Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Intravenous soya oil‐derived (n‐6) fatty acid‐based lipid emulsion vs intravenous fish oil‐derived (n‐3) fatty acid‐based lipid emulsion Percentage of participants achieving a PASI 75 or PGA of 1 or 2 · guttate psoriasis Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Penicillin vs no treatment Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs no treatment Risk of having at least one relapse at long‐term · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs vitamin C Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · chronic plaque psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs vitamin C Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · chronic plaque psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs vitamin C Risk of having at least one relapse at long‐term · chronic plaque psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Rifampicin vs placebo Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Rifampicin vs placebo Proportion of participants with adverse events and severe adverse events · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Rifampicin vs placebo Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Rifampicin vs placebo Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Rifampicin vs placebo Risk of having at least one relapse at long‐term · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy vs no intervention Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · chronic plaque psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy vs no intervention Risk of having at least one relapse at long‐term · chronic plaque psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Penicillin vs no treatment Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Penicillin vs no treatment Risk of having at least one relapse at long‐term · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs no treatment Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs no treatment Proportion of participants with adverse events and severe adverse events · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs no treatment Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Erythromycin vs no treatment Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis Antistreptococcal interventions for guttate and chronic plaque psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Dietary intervention vs usual care Time to relapse Not measured · people with psoriasis Lifestyle changes for treating psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Dietary intervention and exercise programme vs information only Quality of life Not measured · people with psoriasis Lifestyle changes for treating psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Dietary intervention and exercise programme vs information only Time to relapse Not measured · people with psoriasis Lifestyle changes for treating psoriasis (2019) · Cochrane | no estimate extracted | NR | No studies |
Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention) Primary outcome 1. Mean change in patient‐assessed symptoms Pruritus was assessed once as part of SCORAD · children with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Fexofenadine 120 mg/d vs placebo (1‐week intervention) Secondary outcome 2. Mean change in quality of life · adults with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Loratadine 10 mg/d vs placebo (4‐week intervention) Secondary outcome 2. Mean change in quality of life · male and female adults aged 15 years and older with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Loratadine 10 mg/d vs placebo (4‐week intervention) Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ · male and female adults aged 15 years and older with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Loratadine 10 mg/d vs placebo (2‐week intervention) Secondary outcome 2. Mean change in quality of life · male and female adults with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Loratadine 10 mg/d vs placebo (2‐week intervention) Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ · male and female adults with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention) Secondary outcome 2. Mean change in quality of life · children with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |
Cetirizine 10 mg/d vs placebo (4‐week intervention) Secondary outcome 2. Mean change in quality of life · adults with eczema Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema (2019) · Cochrane | no estimate extracted | NR | No studies |